348 related articles for article (PubMed ID: 21836632)
1. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.
Harvey TJ; Hennig IM; Shnyder SD; Cooper PA; Ingram N; Hall GD; Selby PJ; Chester JD
Cancer Gene Ther; 2011 Nov; 18(11):773-84. PubMed ID: 21836632
[TBL] [Abstract][Full Text] [Related]
2. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects.
Yu B; Zhang Y; Zhan Y; Zha X; Wu Y; Zhang X; Dong Q; Kong W; Yu X
Oncol Rep; 2011 Jul; 26(1):255-64. PubMed ID: 21573500
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer.
Greco O; Joiner MC; Doleh A; Powell AD; Hillman GG; Scott SD
Gene Ther; 2006 Feb; 13(3):206-15. PubMed ID: 16307003
[TBL] [Abstract][Full Text] [Related]
4. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
5. [HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter].
Wang WD; Chen ZT; Li DZ; Duan YZ; Wang ZX; Cao ZH
Ai Zheng; 2004 Jul; 23(7):788-93. PubMed ID: 15248913
[TBL] [Abstract][Full Text] [Related]
6. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
Sekar TV; Foygel K; Willmann JK; Paulmurugan R
Gene Ther; 2013 May; 20(5):529-37. PubMed ID: 22914496
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter.
Ido A; Uto H; Moriuchi A; Nagata K; Onaga Y; Onaga M; Hori T; Hirono S; Hayashi K; Tamaoki T; Tsubouchi H
Cancer Res; 2001 Apr; 61(7):3016-21. PubMed ID: 11306481
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
10. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
Kuriyama N; Kuriyama H; Julin CM; Lamborn KR; Israel MA
Cancer Res; 2001 Mar; 61(5):1805-9. PubMed ID: 11280727
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Chen MJ; Green NK; Reynolds GM; Flavell JR; Mautner V; Kerr DJ; Young LS; Searle PF
Gene Ther; 2004 Jul; 11(14):1126-36. PubMed ID: 15164095
[TBL] [Abstract][Full Text] [Related]
12. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
Bilsland AE; Anderson CJ; Fletcher-Monaghan AJ; McGregor F; Evans TR; Ganly I; Knox RJ; Plumb JA; Keith WN
Oncogene; 2003 Jan; 22(3):370-80. PubMed ID: 12545158
[TBL] [Abstract][Full Text] [Related]
13. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
[TBL] [Abstract][Full Text] [Related]
15. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.
Lipinski KS; Djeha AH; Krausz E; Lane DP; Searle PF; Mountain A; Wrighton CJ
Gene Ther; 2001 Feb; 8(4):274-81. PubMed ID: 11313801
[TBL] [Abstract][Full Text] [Related]
16. Use of protamine to augment adenovirus-mediated cancer gene therapy.
Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
[TBL] [Abstract][Full Text] [Related]
17. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
Rancourt C; Bergeron C; Lane D; Garon G; Piché A
Cytotherapy; 2003; 5(6):509-22. PubMed ID: 14660047
[TBL] [Abstract][Full Text] [Related]
18. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
19. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Palmer DH; Mautner V; Mirza D; Oliff S; Gerritsen W; van der Sijp JR; Hubscher S; Reynolds G; Bonney S; Rajaratnam R; Hull D; Horne M; Ellis J; Mountain A; Hill S; Harris PA; Searle PF; Young LS; James ND; Kerr DJ
J Clin Oncol; 2004 May; 22(9):1546-52. PubMed ID: 15051757
[TBL] [Abstract][Full Text] [Related]
20. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]